J&J wins FDA Sustenna nod; EU watchdog takes EMA to task over Humira; Recipharm has acquires Portugals Lusomedicamenta;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@EricPFierce: ICYMI: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More | Follow @EricPFierce

@CarlyHFierce: Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal. Story | Follow @CarlyHFierce

> The FDA has green-lighted Johnson & Johnson's ($JNJ) long-acting antipsychotic Invega Sustenna for schizoaffective disorder. More

> An EU watchdog has taken issue with the EMA over the redaction of clinical study reports for AbbVie's ($ABBV) Humira. Story

> Medecins Sans Frontières' public appeal for Ebola vaccine development in September came months too late, a group veteran says. More

> Sun Pharmaceutical is reworking its deal to buy Ranbaxy Laboratories to address concerns of regulators in India that it will hold too prominent a position there. Story

> Swedish CDMO Recipharm has acquired Portuguese competitor, Lusomedicamenta, in a deal valued at €112.3 million ($140 million.) Release

> Valeant Pharmaceutical ($VRX) has completed a $12 million renovation of its headquarters in Bridgewater, NJ. Release

Medical Device News

@FierceMedDev: Glooko merges tech data to avoid activity-triggered hypoglycemic events. More | Follow @FierceMedDev

@VarunSaxena2: Philips, Duke to collaborate on infant temperature monitoring using InnerSense probe. Article | Follow @VarunSaxena2

@EmilyWFierce: $BSX ordered to pay $26.7M in one of first federal trials over vaginal mesh devices. Story | Follow @EmilyWFierce

> Monteris nabs $30M to grow its less invasive neurosurgery tech. Story

> St. Jude 'looking' to expand production and services operations in Malaysia. More

Biotech News

@FierceBiotech: IPOs: $FGEN comes up big while $NDRM limps out of the gate. Story | Follow @FierceBiotech

@JohnCFierce: Puma drug neratinib flunks PFS, ORR endpoints. Article | Follow @JohnCFierce

@DamianFierce: $GERN rides again as $JNJ partners up on imetelstat for up to $900M. Release | Follow @DamianFierce

> Alexion co-founder will retire in January. Chutes & Ladders

> Boehringer taps WellPoint's outcomes data to develop new a-fib drugs. More

> J&J bets up to $935M that Geron's drug can shake a checkered past. Article

And Finally... A U.S. advisory panel has recommended for the first time to partially strike a long-standing ban preventing gay and bisexual men from donating blood. More

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.